An overview on personalisation of radiotherapy prescriptions in locally advanced non-small cell lung cancer: Are we there yet?

Standard of care radiotherapy in LA-NSCLC is 60–66 Gy in 30–33 fractions. However outcomes for these patients are poor with 5-year survival in the range of 10–20%. Randomised controlled trials have shown that dose escalation in a linear fashion does not improve outcomes for all patients, thus there is a need to tailor the prescription to the individual patient. This review assesses the strategies published to personalise the radiation therapy dose prescription in LA-NSCLC. A systematic and scoping search of the literature was performed to identify studies that met the inclusion criteria.

https://ift.tt/2t6w7mj